<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Evommune, Inc. — News on 6ix</title>
<link>https://6ix.com/company/evommune-inc</link>
<description>Latest news and press releases for Evommune, Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/evommune-inc" rel="self" type="application/rss+xml" />
<item>
<title>Evommune to Host KOL Webinar on April 13, 2026 Highlighting the Potential of MRGPRX2 Inhibition in Migraine</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-to-host-kol-webinar-on-april-13-2026-highlighting-the-potential-of-mrgprx2-inhibition-in-migraine</guid>
<pubDate>Mon, 06 Apr 2026 13:00:00 GMT</pubDate>
<description>PALO ALTO, Calif. & NEW YORK, April 06, 2026--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced it will host a webinar highlighting the migraine treatment landscape and the role of MRGPRX2 inhibition on this debilitating condition on Monday, April 13, 2026, at 11:00 a.m. PT (2:00 p.m. ET).</description>
</item>
<item>
<title>Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights-33</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights-33</guid>
<pubDate>Thu, 05 Mar 2026 21:01:00 GMT</pubDate>
<description>PALO ALTO, Calif. & NEW YORK, March 05, 2026--Evommune, Inc. (NYSE: EVMN) ("Evommune" or the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update.</description>
</item>
<item>
<title>Evommune Announces $125 Million Private Placement</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-announces-125-million-private-013000793</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-announces-125-million-private-013000793</guid>
<pubDate>Fri, 13 Feb 2026 01:30:00 GMT</pubDate>
<description>PALO ALTO, Calif. & NEW YORK, February 13, 2026--Evommune, Inc. ("Evommune" or the "Company") (NYSE: EVMN), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that it has entered into a securities purchase agreement to sell 4,494,279 shares of its common stock to a select group of new and existing mutual funds and dedicated healthcare institutional investors in a private placement. The purchase price of</description>
</item>
<item>
<title>Evommune Announces Positive Top-line Data from Phase 2a Proof-of-Concept Trial of EVO301 in Moderate-to-Severe Atopic Dermatitis</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-announces-positive-top-line-123000560</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-announces-positive-top-line-123000560</guid>
<pubDate>Tue, 10 Feb 2026 12:30:00 GMT</pubDate>
<description>PALO ALTO, Calif. & NEW YORK, February 10, 2026--Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced positive top-line results from its randomized, double-blind, placebo-controlled Phase 2a trial evaluating EVO301. This long-acting fusion protein consisting of an interleukin-18 (IL-18) binding protein and an anti-serum albumin Fab-associated doma</description>
</item>
<item>
<title>Evommune Reports Third Quarter 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-reports-third-quarter-2025-210500540</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-reports-third-quarter-2025-210500540</guid>
<pubDate>Thu, 11 Dec 2025 21:05:00 GMT</pubDate>
<description>PALO ALTO, Calif., December 11, 2025--Evommune, Inc. (NYSE: EVMN) (the "Company"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update.</description>
</item>
<item>
<title>Evommune Announces Pricing of its Initial Public Offering</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-announces-pricing-initial-public-004500746</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-announces-pricing-initial-public-004500746</guid>
<pubDate>Thu, 06 Nov 2025 00:45:00 GMT</pubDate>
<description>Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced the pricing of its initial public offering of 9,375,000 shares of common stock at an initial public offering price of $16.00 per share. In addition, Evommune has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the initial public offering price, less underwriting di</description>
</item>
<item>
<title>Evommune Announces Commencement of Initial Public Offering</title>
<link>https://6ix.com/company/evommune-inc/news/evommune-announces-commencement-initial-public-103000239</link>
<guid isPermaLink="true">https://6ix.com/company/evommune-inc/news/evommune-announces-commencement-initial-public-103000239</guid>
<pubDate>Thu, 30 Oct 2025 10:30:00 GMT</pubDate>
<description>Evommune, Inc. ("Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today announced that on October 17, 2025, it filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the "SEC") in connection with the commencement of a proposed initial public offering of its common stock. Evommune is offering 9,375,000 shares of its common stock at an expected initial public offering p</description>
</item>
</channel>
</rss>